2020
DOI: 10.1111/dom.14268
|View full text |Cite
|
Sign up to set email alerts
|

Cost‐effectiveness analysis of empagliflozin versus sitagliptin as second‐line therapy for treatment in patients with type 2 diabetes in the United States

Abstract: Aim To estimate the cost‐effectiveness of sequential addition of empagliflozin versus sitagliptin after metformin in patients with type 2 diabetes (T2D) with or without cardiovascular disease (CVD) from the perspective of the US healthcare payer. Methods An individual simulation model predicted lifetime diabetes‐related complications, using UKPDS‐OM2 equations in patients without CVD, and EMPA‐REG OUTCOME equations in patients with CVD. Additional US‐based sources informed inputs for population characteristics… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
2

Citation Types

4
33
0

Year Published

2022
2022
2023
2023

Publication Types

Select...
8

Relationship

1
7

Authors

Journals

citations
Cited by 20 publications
(37 citation statements)
references
References 34 publications
4
33
0
Order By: Relevance
“…32 Providers may be wary of prescribing medications if costs are high or unclear based on the payor. 33 Thus, despite the cost-effectiveness of SGLT-2i, 34,35 affordability of SGLT-2i may contribute to low uptake and delays in care.…”
Section: Discussionmentioning
confidence: 99%
“…32 Providers may be wary of prescribing medications if costs are high or unclear based on the payor. 33 Thus, despite the cost-effectiveness of SGLT-2i, 34,35 affordability of SGLT-2i may contribute to low uptake and delays in care.…”
Section: Discussionmentioning
confidence: 99%
“…Results of this analysis build on the available evidence showing that empagliflozin has economic benefits in various settings compared with different antidiabetic agents, and in a broader T2D population and in patients with T2D and established CVD. 6 , 12 , 29 , 30 , 31 , 32 , 33 , 34 , 35 Notably, other economic evaluations have identified empagliflozin as a dominant strategy versus liraglutide for the treatment of patients with T2D. 36 , 37 Using the IQVIA Core Diabetes Model, empagliflozin has been compared with liraglutide, both in addition to background standard of care therapies, in patients with T2D with established CVD in the UK and Denmark based on data from the EMPA‐REG OUTCOME and LEADER CVOTs.…”
Section: Discussionmentioning
confidence: 99%
“…This study was conducted using a previously published model for the United States that assessed sequential treatment with second‐line empagliflozin versus sitagliptin, with appropriate modifications to reflect clinical efficacy, drug adverse events (AEs), health‐related quality of life (QoL), and costs with liraglutide. 6 …”
Section: Introductionmentioning
confidence: 99%
“…It exerts its pharmacological action by reducing basal and postprandial blood glucose [5]. Although metformin controls the hyperglycemic conditions in patients well, the combination of metformin and sitagliptin is to date the sole combination that is declared advantageous in terms of no weight gain and improving hypoglycemic situation [6][7][8]. However, conventional dosage forms lead to uncontrolled drug release, instability and less bioavailability of metformin [9].…”
Section: Introductionmentioning
confidence: 99%